Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Novita Healthcare’s TALi platform continues as an approved and registered provider by the National Disability Insurance Agency, or the NDIA
  • The NDIA has shown further support by making it accessible via three registration classes that fall under the National Disability Insurance Scheme
  • This scheme will roll out next year and will help support over 460,000 Australians living with disabilities
  • The TALi technology falls under this group as it helps children with neurodevelopment disorders to concentrate better and avoid distractions
  • Company shares are up a healthy 11.6 per cent, with shares trading for 9.2 cents each

Novita Healthcare’s TALi Health platform continues as an approved and registered provider by the National Disability Insurance Agency (NDIA).

The NDIA has shown further support of the early childhood education platform by making it accessible via three registration classes.

The TALi technology was designed by neuroscientists at Monash University who recognised the lack of treatment and learning options for children with neurodevelopment disorders.

The program helps children concentrate on learning at school. It also teaches children to avoid fidgeting, prevent impulsive behaviour, and avoid distractions.

TALi Health products are now accessible through the 0103 Assist Prod-Pers Care/Safety, 0116 Innov Community Participation and 0124 Comms and Info Equipment classes.

These classes fall under the National Disability Insurance Scheme (NDIS) and will allow participants to fund and access TALi products.

The NDIS is an Australian Government scheme which funds costs associated with disabilities. The NDIS was legislated in 2013 and is expected to be in full operation next year.

When it is fully rolled out, the NDIS will provide around 460,000 Australians aged under 65, who have a permanent or significant disability, with funding for support and services.

Novita Managing Director Glenn Smith is pleased children and their families will be able to access TALi products with little costs.

“The NDIS is an insurance scheme funded by the Australian taxpayer and it is appropriate that children with developmental delay disorders or Autism Spectrum Disorder as examples, will be able to access TALi products via their self-managed plans with no out of pocket cost,” he said.

In the September 2019 quarter, Novita recruited additional resources to focus on expanding TALi internationally and secure global insurance schemes (including NDIS).

On November 1, the company announced its FDA-cleared TALi Train will be delivered through the U.S. Reimbursement Code system.

There are reportedly over eight million children in the U.S. who are diagnosed with ADHD or autism and TALi Train will be used as a treatment option.

Novita Healthcare shares are up a healthy 11.6 per cent, with shares trading for 9.2 cents each at 11:18 am AEDT.

NHL by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.